INVO Fertility, Inc (NASDAQ:IVF) Short Interest Update

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 94,554 shares, an increase of 281.1% from the November 30th total of 24,811 shares. Approximately 4.0% of the company’s stock are short sold. Based on an average daily trading volume, of 982,155 shares, the short-interest ratio is presently 0.1 days. Based on an average daily trading volume, of 982,155 shares, the short-interest ratio is presently 0.1 days. Approximately 4.0% of the company’s stock are short sold.

INVO Fertility Stock Down 4.2%

Shares of IVF traded down $0.04 during mid-day trading on Friday, hitting $0.84. The stock had a trading volume of 87,760 shares, compared to its average volume of 313,570. INVO Fertility has a fifty-two week low of $0.82 and a fifty-two week high of $299.52. The company has a market cap of $2.00 million, a PE ratio of 0.00 and a beta of 2.54. The company’s fifty day simple moving average is $3.04 and its two-hundred day simple moving average is $10.75.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INVO Fertility in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Institutional Trading of INVO Fertility

A hedge fund recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC purchased a new position in INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.